Karen Ignagni: Bending the curve -- and the truth -- about the $1000 Pill

  • by: |
  • 08/04/2014
Karen Ignagni's WSJ oped claims that spending on the new Hepatitis C (HCV) drug will hike health premiums and bring insurers to ruin. 

In fact, new drugs like Sovaldi will not only rescue patients, but also reduce the cost of health care.  The reason is simple. Cure are always less expensive than treating the same disease using no or halfway measures.  Would Ignagni wail about a cure for Ebola that cost $1000 a pill?

Before HIV medicines came to market, there were nearly 100000 people with HIV were hospitalized.   Today, about 38000 HIV patients are hospitalized each year.  Hospitalization rates plummeted thanks to HIV drugs. Without HIV medicines, 111000 HIV patients would be hospitalized each year.    Fewer people with HIV would be alive.

Sovaldi will produce similar savings.  Millman (a health actuarial firm) estimates 984510 with HCV will be treated between 2014 and 2020.  Assume everyone treated gets Sovaldi at $80000.  That would cost $78 billion or more accurately about $13 billion a year for six years.

Sounds dire right?  But Ignagni ignores how new HCV drugs eliminates a 48-week course of treatment for interferon (that is only effective half the time and has flu like side effects) costs about $6.12 billion year.   If hospitalization rates drop by half, it will save another $1 billion per year.  ($7 billion total.)   Over six years insurers will save $252 billion in the process.  Insurers will net savings of $174 billion.   

None of this takes into account that new HCV drugs increase life expectancy and well being so that people can work, pay taxes and cover the cost of health premiums.   Ignagni’s alarms about Sovaldi are intended to divert attention to these facts and to justify sticking more consumers with the cost of a treatment that saves lives and money. 
CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog